First-line eradication rates comparing two shortened non-bismuth quadruple regimens againstHelicobacter pylori: an open-label, randomized, multicentre clinical trial
Journal of Antimicrobial Chemotherapy
Objectives: Helicobacter pylori eradication remains a challenge. Non-bismuth-based quadruple regimens (NBQR) have shown high eradication rates (ER) elsewhere that need to be locally confirmed. The objective of this study was to compare the first-line ER of a hybrid therapy (20 mg of omeprazole twice daily and 1 g of amoxicillin twice daily for 10 days, adding 500 mg of clarithromycin twice daily and 500 mg of metronidazole every 8 h for the last 5 days; OA-OACM) with that of a 10 day
... a 10 day concomitant regimen consisting of taking all four drugs twice daily every day (including 500 mg of metronidazole every 12 h; OACM). A 10 day arm with standard triple therapy (OAC; 20 mg of omeprazole/12 h, 1 g of amoxicillin/12 h and 500 mg of clarithromycin/12 h) was included. Patients and methods: Three hundred consecutive patients were randomized (1: 2: 2) into one of the three following regimens: (i) OAC (60); (ii) OA-OACM (120); and (iii) OACM (120). Eradication was generally confirmed by a [ 13 C]urea breath test at least 4 weeks after the end of treatment. Adverse events and compliance were assessed. EudraCT: 2011-006258-99. Results: ITT cure rates were: OAC, 70.0% (42/60) (95% CI: 58.3 -81.7); OA-OACM, 90.8% (109/120) (95% CI: 85.6 -96.0); and OACM, 90.0% (107/119) (95% CI: 84.6 -95.4). PP rates were: OAC, 72.4% (42/58) (95% CI: 60.8 -84.1); OA-OACM, 93.9% (108/115) (95% CI: 89.5 -98.3); and OACM, 90.3% (102/113) (95% CI: 84.8 -95.8). Both NBQR significantly improved ER compared with OAC (P, 0.01), but no differences were seen between them. Mean compliance was elevated [98.0% (SD ¼9.8)] with no differences between groups. There were more adverse events in the quadruple arms (OACM, 65.8%; OA-OACM, 68.6%; OAC, 46.6%; P,0.05), but no significant differences between groups in terms of severity were seen. Conclusions: Hybrid and concomitant regimens show good ER against H. pylori infection with an acceptable safety profile. They clearly displace OAC as first-line regimen in our area.